List of Inrebic drug patents
Inrebic is owned by Impact.
Inrebic contains Fedratinib Hydrochloride.
Inrebic has a total of 5 drug patents out of which 0 drug patents have expired.
Inrebic was authorised for market use on 16 August, 2019.
Inrebic is available in capsule;oral dosage forms.
Inrebic can be used as treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring thiamine levels and administering thiamine or a thiamine equivalent, treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis.
Drug patent challenges can be filed against Inrebic from 2023-08-17.
The generics of Inrebic are possible to be released after 24 September, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7528143 | IMPACT | Bi-aryl meta-pyrimidine inhibitors of kinases |
Dec, 2026
(3 years from now) | |
| US7825246 | IMPACT | Bi-aryl meta-pyrimidine inhibitors of kinases |
Dec, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8138199 | IMPACT | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
Jun, 2028
(5 years from now) | |
| US10391094 | IMPACT | Compositions and methods for treating myelofibrosis |
Jun, 2032
(9 years from now) | |
| US11400092 | IMPACT | Methods of treating myeloproliferative disorders |
Sep, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 16, 2026 |
| New Chemical Entity Exclusivity (NCE) | Aug 16, 2024 |
Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient
NCE-1 date: 2023-08-17
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis; Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring thiamine levels and administering thiamine or a thiamine equivalent
Dosage: CAPSULE;ORAL
INREBIC family patents
21
United States
6
Korea, Republic of
5
Brazil
5
China
4
Russia
4
Japan
4
Ukraine
4
Australia
3
New Zealand
3
Lithuania
3
Canada
3
Israel
3
European Union
2
Singapore
2
Malaysia
2
Spain
2
Mexico
2
Morocco
2
Taiwan, Province of China
2
South Africa
2
Hungary
2
Chile
2
Denmark
1
Portugal
1
Croatia
1
Colombia
1
Dominican Republic
1
Norway
1
Peru
1
Hong Kong
1
Tunisia
1
EA
1
Nicaragua
1
Cyprus
1
Poland
1
Ecuador
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic